Table 4.
Clinical studies with combined PD-1 and CTLA-4 inhibitors in metastatic UM patients.
| Study Type | Therapy | Patients Enrolled | ORR | DCR | mPFS | mOS | Reference |
|---|---|---|---|---|---|---|---|
| Single arm, phase II | Nivolumab and ipilimumab | 52 | 11.5% | 63.5% (1CR,5PR,27SD) |
3 months | 12.7 months | [75] NCT02626962 |
| Single arm, phase II | Nivolumab and ipilimumab | 35 (33 evaluable) |
18% | 51.5% (1CR,5PR,11SD) |
5.5 months | 19.1 months | [72] |
| Retrospective | PD-1 inhibitor and ipilimumab | 15 (12 evaluable) |
16.7% | 33.3% (2PR,2SD) |
2.8 months | NR | [70] |
| Multicenter, retrospective | Nivolumab/pembrolizumab and ipilimumab | 64 | 15.6% | 37.5% (2CR,8PR,14SD) |
3 months | 16.1 months | [76] |
| Multicenter, retrospective | Ipilimumab and nivolumab | 89 | 11.6% | 36% (1CR,9PR,21SD) |
2.7 months | 15 months | [77] |
| Retrospective population-based | Ipilimumab and nivolumab | 19 | 21.1% | 31.6% (4PR,2SD) |
3.7 months | 18.9 months | [54] |
| Single center, retrospective |
Ipilimumab and nivolumab in combination with TACE | 8 | 25% | 75% (2PR,4SD) |
NR | 14 months | [78] |
| Multicenter, retrospective | PD-1 inhibitor and CTLA-4 inhibitor (dual ICI) | Cohort A (liver metastases only) 34 |
8.7% | 35.3% (3PR,9SD) |
NR | NR | [56] |
| Cohort B (several metastatic sites) 60 |
16.7% | 43.3% (10PR,16SD) |
NR | NR | |||
| Total 94 | 13.8% | 40.4% (13PR,25SD) |
NR | NR |
ORR, overall response rate; DCR, disease control rate; mPFS, median progression-free survival; mOS, median overall survival; NR, not reported; CR, complete response; PR, partial response; SD, stable disease; TACE, transarterial chemoembolization; ICI, immune checkpoint inhibitor.